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ABSTRACT 14 
Objectives: To characterize the frequency and detailed anatomic sites of failure for patients 15 
receiving post-radical prostatectomy (RP) salvage radiation therapy (SRT). 16 
 17 
Materials/Methods: A multi-institutional retrospective study was performed on 574 men who 18 
underwent SRT between 1986 and 2013.  Anatomical recurrence patterns were classified as 19 
lymphotropic (lymph nodes only), osteotropic (bone only), or multifocal if both were present. 20 
Isolated first failure sites were defined as sites of initial clinically detected recurrence that 21 
remained isolated for at least 3 months.  22 
 23 
Results: The median follow-up post-SRT was 6.8 years. The 8-year rates of local, regional, and 24 
distant failure for patients undergoing SRT were 2%, 6%, and 21%, respectively.  Of the 128 of 25 
574 men (22%) who developed a clinically detectable recurrence, 17%, 50%, and 31% were 26 
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lymphotropic, osteotropic, and multifocal, respectively.  The tropic nature of metastases was 27 
prognostic for distant metastases-free survival (DMFS) and prostate cancer specific survival 28 
(PCSS); the 10-year rates of DMFS were 18%, 5%, and 7% (p<0.01), and PCSS were 78%, 29 
68%, and 56% (p<0.01), for lymphotropic, osteotropic, and multifocal failure patterns, 30 
respectively.   31 
 32 
Conclusions: We demonstrate that tropism for metastatic site has significant prognostic impact 33 
on PCSS in men treated with SRT. Radiographic local failure is an uncommon event after SRT 34 
when compared to historical data of patients treated with surgery monotherapy.  However, 35 
distant failure remains a challenge in this patient population and warrants further therapeutic 36 
investigation. 37 
 38 
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Introduction 59 
Understanding patterns of treatment failure is critical in defining how best to further 60 
escalate or de-intensify therapy.  In prostate cancer, the primary pattern of failure following 61 
definitive radiation therapy (RT) or radical prostatectomy (RP) is local.  Despite the great 62 
concern for micrometastatic disease, even men who have high risk prostate cancer most 63 
commonly recur locally, accounting for approximately 50% of all clinically detectable 64 
recurrences following prostatectomy or definitive RT (1-3).  Importantly, local control has been 65 
demonstrated to correlate with the development of distant metastases (DM) as well as prostate-66 
cancer specific survival (4-7).   67 
For men that choose to undergo RP for high risk disease it is important to counsel them 68 
on the high recurrence rates following surgery alone with estimated 5-year rates of biochemical 69 
failure of 50-75% (8). The use of adjuvant radiotherapy (ART) can reduce progression rates by 70 
50% as demonstrated in 3 randomized controlled trials (3, 9, 10).  However, the use of ART 71 
occurs in <10% of men who undergo RP who have high risk features, and it is increasingly 72 
common for patients to undergo salvage RT (SRT) once they have biochemically recurred (11).  73 
Given the increased utilization of surgery for high risk disease, and continued low rate of ART 74 
use, the patterns of failure in this setting are poorly described (12). 75 
The patterns of failure after SRT are critical to better understand how to improve patient 76 
outcomes.  For this reason, we aimed to characterize the patterns of failure after SRT and to 77 
determine if predominant tropic patterns of failure are prognostic for patient outcomes.  Herein, 78 
we report results of a large multicenter study assessing patterns of failure for a cohort of men 79 
treated with RP followed by SRT. 80 
 81 
Materials and Methods 82 
Patient Selection 83 
 A multi-institutional study was performed on 574 men who underwent a RP with a 84 
standard pelvic lymph node dissection and then received post-operative external beam SRT 85 
between 1986 and 2013.   These men were selected from a cohort of 657 consecutively treated 86 
men receiving adjuvant or salvage radiation therapy following prostatectomy.  Excluding men 87 
whom received adjuvant radiation and those with positive pelvic lymph nodes resulted in 574 88 
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remaining men.  Analysis of these men was approved by local institutional review boards at all 89 
involved institutions.     90 
 91 
Treatment  92 
 All men were treated with external beam SRT with the use of either three-dimensional 93 
conformal RT or intensity-modulated RT.  SRT was defined as post-RP radiation delivered in the 94 
presence of a detectable PSA (most common reason) or commencing greater than 4 months 95 
following RP. The clinical target volume (CTV) was defined as the prostate bed.  The planning 96 
target volume consisted of the CTV plus a uniform 0.5- 1.0 cm expansion, dependent on the use 97 
and modality of daily imaging.  The median dose delivered to the planning target volume (PTV) 98 
was 68.4 Gy with an interquartile range (IQR) of 64.8 to 68.4 Gy, delivered in daily 1.8 Gy 99 
fractions.  Men with high-risk clinicopathologic features were selectively treated to the pelvic 100 
lymph nodes (19%, n=23) and/or received neoadjuvant and concurrent androgen deprivation 101 
therapy (ADT) (25%, n=31), at the treating physician’s discretion.  If pelvic lymph nodes were 102 
treated they received 45 Gy in 1.8 Gy daily fractions. 103 
  104 
End points 105 
 Clinically detected recurrences were discovered primarily through CT based imaging or 106 
bone scintigraphy.   Lymph node recurrences were most commonly identified on CT based 107 
imaging.  Lymph nodes were considered suspicious if > 8 mm in size in the pelvis or > 1 cm in 108 
the retroperitoneum, or with abnormal shape (rounded),  loss of a fatty hilum, inhomogeneity, or 109 
clear increase in size of a lymph node from prior imaging in the appropriate clinical context, 110 
such as a rising PSA.   All imaging was read by radiologists at one of the treating institutions; 111 
however there was no repeat central review for this analysis.  Imaging was typically performed at 112 
the time of post-radiation biochemical recurrence, and then as clinically indicated following this 113 
(normally at least every 6 months for men with metastatic disease).  The locations of first disease 114 
recurrence or metastatic site were grouped as local (prostate bed), confined to pelvic lymph 115 
nodes (external and internal iliac, presacral, and obturator lymph node stations), 116 
retroperitoneal/abdominal lymph nodes, thoracic lymph nodes, bone, or viscera.  An isolated site 117 
of first recurrence was defined as any recurrence limited to a single anatomic location in any of 118 
the above groupings for at least 3 months before discovery of additional sites of involvement, as 119 
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proposed by Zumsteg and Spratt et al (2).  Men were also grouped based on their pattern of 120 
failure and were defined as having lymphotropic, osteotropic, or multifocal patterns of failure.  121 
All patients with visceral failures had multi-site failure, and as such are included in the 122 
multifocal pattern of failure.  Lymphotropic and osteotropic patterns of failure were defined as 123 
metastatic disease confined to lymph nodes or bone alone, respectively, for at least two years 124 
from initial clinical detection before discovery of involvement of an additional site (2).  Patients 125 
with multiple anatomic locations involved within the first two years of a clinically detected 126 
recurrence were defined as having a multifocal pattern of failure.  The time to a recurrence was 127 
defined as the time from the date of salvage radiation therapy to the date of the imaging study 128 
that identified radiographic evidence of recurrence. 129 
 Biochemical failure following SRT was defined as a rising prostate-specific antigen 130 
(PSA) level ≥0.2 ng/mL from the post-SRT PSA nadir, or any PSA level ≥ 0.5 ng/mL.  Prostate-131 
cancer specific mortality (PCSM) was defined as a death in any man with progressive metastatic 132 
disease or castration-resistant prostate cancer.  The time to development of metastases and 133 
PCSM was assessed from the time of biochemical failure following RP.   134 
  135 
Statistical analysis 136 
Descriptive statistics were used to describe first sites of failure as well as patterns of 137 
failure.  Adjusted Kaplan-Meier methods controlling for patient age at the time of RT were used 138 
to assess distant metastases-free survival (DMFS) and prostate cancer-specific survival (PCSS) 139 
from the time of post-RP biochemical failure. A step-wise multivariate model was created using 140 
Cox-proportional hazards analysis for DMFS and PCSS.  For all statistical analyses, two-tailed 141 
P-values of <0.05 were considered statistically significant. Statistical analyses were performed 142 
using IBM SPSS version 21.0 (SPSS Inc., Chicago, IL USA) and MedCalc V16.4.3 (MedCalc 143 
Software, Mariakerke, Belgium). 144 
 145 
Results 146 
Patient characteristics 147 
 The median follow-up post-SRT was 6.8 years (IQR 3.9-10.2).   The median time from 148 
RP to SRT was 24 months (IQR 11-49).  Patient characteristics for the men who developed 149 
metastases can be found in Table 1; 74.2% of men had high-risk prostate cancer based on NCCN 150 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
criteria at the time of prostatectomy, 75.5% had Gleason grade group 3-5 (Gleason 4+3 to 10) 151 
disease (8, 13, 14), 69.9% were pathologic stage T2b-T4, and the median pre-RT PSA was 0.7 152 
ng/mL (interquartile range [IQR] 0.4-1.4). 153 
 A total of 128 of 574 men (22.3%) developed clinically detectable recurrent prostate 154 
cancer following biochemical recurrence post-RP.  No patient experienced a distant recurrence 155 
without a preceding biochemical recurrence.  An additional 3 men had a local only recurrence 156 
without developing metastases.  The median time to post-RP biochemical recurrence for these 157 
128 men was 11.9 months (IQR 5.0-24.8).  The median time from post-RP BF to development of 158 
metastases was 32.5 months (IQR 11.4-64.2).   159 
 160 
Patterns of isolated first recurrences 161 
 Table 2 demonstrates the sites of isolated first recurrences as well as the total distribution 162 
of clinically detectable recurrences.  104 patients (developed an isolated first recurrence (i.e. 163 
disease located to a single site for at least 3 months).  The most common site of isolated first 164 
failure was bone (63.5%), followed by retroperitoneal/abdominal lymph nodes (12.5%) and then 165 
pelvic lymph nodes (11.5%). Only one patient with an isolated pelvic lymph node failure 166 
received pelvic nodal irradiation.  This was a left obturator node failure and was within the 167 
radiation treatment field.  Isolated local first failures were rare with 5 in total (4.8%).   168 
 169 
Overall patterns of failure  170 
From our entire cohort of 574 men receiving post-RP SRT 8-year incidences of all 171 
anatomic sites of failure were calculated (Table 3) (2).  8-year actuarial rates of local failure 172 
were 2.2%, pelvic nodal failure was 6.0%, and distant failure was 21.0% (Figure 1). Men with 173 
NCCN high risk disease at time of RP had 8-year rates of local, regional, and distant failure of 174 
2.5%, 6.2%, and 29.1%, respectively. 175 
 176 
Metastatic tropism and impact on outcome 177 
 The tropism of recurrences was able to be determined for 120 of the 128 men (93.8%) 178 
who developed metastases.  62 men had osteotropic disease (51.7%), 19 had lymphotropic 179 
disease (15.8%), and 34 men had multifocal disease (28.3%).  Men with multifocal disease had 180 
higher pre-RT PSA values compared to men with lymphotropic or osteotropic disease, although 181 
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this difference did not reach statistical significance; otherwise patient characteristics were similar 182 
between these three groups (Supplemental Table 1).  On further univariate analysis, the pre-183 
SRT PSA was not associated with either the trophic nature of metastases nor the development of 184 
isolated versus multifocal metastases when assessed as a categorical variable, with commonly 185 
utilized thresholds of 0.2 ng/mL and 0.5 ng/mL, nor as a continuous variable (all p>0.1).  The 186 
tropic nature of metastases was prognostic for DMFS and PCSS.  The 10-year rates of DMFS 187 
were 18%, 5%, and 7% (p=0.046, Figure 2A), and PCSS were 78%, 68%, and 56% (p=0.039, 188 
Figure 2B), for lymphotropic, osteotropic, and multifocal failure patterns, respectively.    189 
 Lastly, we created multivariate models to assess for predictors of metastases and PCSM 190 
following SRT and biochemical recurrence, respectively.  When assessing for predictors of 191 
metastases while controlling for grade group, pre-RT PSA, surgical margin status, pathologic T-192 
stage, use of ADT during RT, and pelvic nodal irradiation (Table 4), retained variables in the 193 
model included grade group 5 (HR 2.2, 95% CI 1.4-3.5, p<0.001), seminal vesicle invasion (HR 194 
2.4, 95% CI 1.5-3.6, p<0.001), pre-SRT PSA (HR 1.2, 95% CI 1.1-1.3, p<0.001) and the 195 
presence of a positive surgical margin (HR 0.4, 95% CI 0.3-0.6, p<0.001).  When assessing for 196 
predictors of PCSM while controlling for grade group, recurrence tropism, pre-RT PSA, surgical 197 
margin status, pathologic T-stage, use of ADT during RT, and age (Table 4), the only variables 198 
retained in the model were grade group 5 (HR 2.4, 95% CI 1.2-4.7, p=0.01) and multifocal 199 
metastatic tropism (HR 2.1, 95% CI 1.1-4.0, p=0.02). 200 
 201 
Discussion 202 
 In a large multicenter study with long-term follow-up we have demonstrated multiple key 203 
findings that we believe are of interest to the urologic oncology community.  First, local failure is 204 
an infrequent event after SRT.  Second, pelvic nodal failure, especially isolated pelvic nodal 205 
failure rates are uncommon despite the omission of pelvic nodal RT in most patients and the lack 206 
of extended pelvic lymph node dissections in our cohort.  Third, distant failure appears to be the 207 
most common form of failure after SRT in contrast to surgery monotherapy or definitive 208 
radiotherapy.  Finally, we validate that tropism for metastatic failure is prognostic for not only 209 
time to metastatic disease but also prostate cancer specific survival. 210 
Local failure after RP monotherapy or definitive RT (+/- ADT) is the most common site 211 
of recurrence and is estimated to occur in 10-50% of patients based on pre-treatment 212 
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characteristics.  Furthermore, ~50% of all recurrences are local (1-3).  We demonstrate that when 213 
utilizing two forms of local therapy (i.e. surgery and SRT), as in our multicenter cohort, that only 214 
5.5% of all recurrences had a local component to them.  Furthermore, the cumulative 8-year 215 
radiographic local failure rate was only 2.2%.   These data demonstrate the high efficacy of SRT 216 
to eliminate local disease, and as such, that further dose-escalation beyond 68.4 Gy is unlikely to 217 
result in demonstrable improvements in local control. 218 
While surveillance CT imaging is a part of the standard of care for assessing men with 219 
recurrent prostate cancer, as done in our study, it has been demonstrated to have poor sensitivity 220 
and specificity in the detection of both local recurrence and lymph node metastases (15).  As 221 
such the true rate of both local recurrence and lymph node metastases in our series is also likely 222 
underreported.  None-the less, our very low 8-year pelvic lymph node recurrence (6.0%) 223 
suggests that these are not common occurrences for men receiving SRT.  Furthermore,  none of 224 
the patients in our cohort received an extended pelvic lymph node dissection, and <20% of 225 
patients received pelvic nodal RT, which questions the potential benefit of elective pelvic nodal 226 
RT. Similar rates of pelvic recurrences have been reported from patients undergoing definitive 227 
radiotherapy without pelvic nodal RT with 8-year rates of pelvic lymph node failure ~4% (2).  228 
However, the benefit of pelvic nodal RT in the salvage setting will definitively be answered by 229 
RTOG 0534 which is now closed and the data is maturing.     230 
While local and regional control were excellent following SRT, development of 231 
metastases remained a common event with approximately 20% of the men in our cohort 232 
developing metastatic disease by 8-years post-SRT.  Furthermore, men with NCCN high risk 233 
disease had nearly a 30% rate of distant metastases at 8-years post-SRT.  There are multiple 234 
potential explanations for these findings.  First, these patients underwent SRT with a median 235 
time between RP and SRT of 24 months.  This time interval potentially allows locally persistent 236 
disease to spread to regional or distant sites.  This raises the question of whether ART may be 237 
ideal to not only achieve excellent local control, but also improve rates of DMFS by eradicating 238 
local disease before it can disseminate. This idea is supported by a detailed patterns of failure 239 
analysis of the SWOG 8794 randomized trial of RP +/- ART, where at a median follow-up of 10 240 
years only 7% of patients who received ART had developed metastases (1).   Patients in our 241 
analysis also had a median pre-SRT PSA level of 0.7 ng/mL.  Recent evidence suggests 242 
improved metastasis-free survival when men receive salvage radiation therapy when the PSA 243 
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level is ≤ 0.5 ng/mL, and even further improved when the pre-SRT PSA is ≤ 0.2 ng/mL  (16, 17).  244 
As such, the elevated pre-SRT PSA levels in our cohort may have in part contributed to the 245 
overall high rate of metastatic progression, and when possible we would recommend initiation of 246 
SRT at the time of biochemical recurrence before the pre-SRT PSA elevated above 0.5 ng/mL 247 
and preferably with the pre-RT PSA as close to 0.2 ng/mL as possible.   248 
Another possible explanation for the high distant failure observed in our analysis is that 249 
ADT was given to only ~25% of men, and ADT has been shown pre-clinically to be a potent 250 
radiosensitizer (18-20).  Additionally, prospective randomized trials (GETUG-AFU 16 and 251 
RTOG 9601) have recently demonstrated improved progression free survival with the addition of 252 
ADT to SRT, primarily in men with pre-SRT >0.7 ng/mL.  Furthermore, RTOG 9601 has long-253 
term follow-up and has demonstrated improvement in DMFS and overall survival with the 254 
addition of ADT to SRT (21, 22).  Our study demonstrated that men with grade group 5, pT3b, 255 
and a high pre-SRT PSA all independently confirmed an increased risk for distant failure 256 
following SRT.  Therefore, the addition of ADT should strongly be considered for men with any 257 
of these risk factors.    258 
Other measures by which to decrease rates of DM in this setting are needed in addition to 259 
ADT.  For men receiving post-operative RT, two prospective trials have demonstrated the safety 260 
of docetaxel in combination with post-RP RT (23, 24). Preliminary results from RTOG 0621, 261 
which assessed the addition of ADT and docetaxel following adjuvant RT, showed improved 262 
progression-free survival compared to historical rates following adjuvant RT alone (24).  Given 263 
the encouraging early results with docetaxel in combination with either definitive (25) or post-264 
RP RT (24), and the high-rate of progression to metastatic disease for men receiving SRT, 265 
additional research is warranted assessing docetaxel or alternative systemic therapies in the 266 
context of SRT. 267 
 Despite the rigor in collecting our data there are multiple limitations that must be 268 
acknowledged. First, our analyses are limited by their retrospective nature. Second, the use of 269 
MRI and more advanced functional imaging were not used which have been shown to have 270 
increased sensitivity in detecting recurrent/metastatic disease (10).  Therefore, all of our failure 271 
rates are likely underestimated.  Additionally, biopsies of recurrent/metastatic sites were not 272 
performed to document true pathologic evidence of prostate cancer.  However, CT imaging and 273 
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bone scans remain standard of care imaging studies for men with recurrent/metastatic prostate 274 
cancer.   275 
   In closing, while local failures are rare following SRT these men remain at increased risk 276 
for progression to metastatic disease.  As demonstrated in recent randomized trials, the use of 277 
ADT in the setting should strongly be considered, especially for men with high pre-SRT PSA, 278 
and future clinical trials are needed to assess the possible benefits of treatment intensification 279 
with docetaxel, second generation anti-androgens, or other novel therapies, as well as companion 280 
biomarkers to better select patients for treatment intensification.   281 
 282 
 283 
 284 
 285 
 286 
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 384 
Figure Legends 385 
Figure 1.  Cumulative incidence of all failures stratified by location (local, regional, or distant) 386 
for the entire cohort of men receiving post-prostatectomy salvage radiation therapy from time of 387 
salvage radiotherapy. 388 
 389 
Figure 2.  Impact of tropic nature on A) distant metastasis-free survival, and B) prostate cancer-390 
specific survival from the time of biochemical failure after salvage radiotherapy.  391 
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Table 1. Characteristics for men developing post-SRT metastases  
 Variable N= or median (IQR) % 
Age (years) 63.8 (57.7-68.2)  
Pre-RP PSA (ng/mL) 7.0 (4.8-12.5)  
Pre-SRT PSA (ng/mL) 0.7 (0.4-1.4)  
Grade Group (Gleason Score) 
    1 (≤6) 
    2 (3+4=7) 
    3 (4+3=7) 
    4 (8) 
    5 (9-10) 
 
6  
24  
41  
19 
33 
 
4.9 % 
19.5 % 
33.3 % 
15.4 % 
26.8 % 
pTstage 
    T2a 
    T2b/c 
    T3a-T4 
 
37 
46 
40 
 
30.1 % 
37.4 % 
32.5 % 
NCCN risk group 
    Low 
    Intermediate 
    High 
 
0  
33 
95 
 
0 % 
25.8 % 
74.2 % 
Positive margins 56 45.5 % 
Positive Lymph nodes 5 4.7 % 
SRT Dose (Gy) 68.4 (64.8-68.4)  
Pelvic nodal RT 23 19.2 % 
Concurrent ADT 31 25.2 % 
ADT duration (months) 6.6 (4.0-15.1)  
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Abbreviations: SRT=salvage radiation therapy, RP=radical prostatectomy, PSA=prostate-
specific antigen, pTstage=pathologic T stage, Gy=Gray, ADT=androgen deprivation therapy 
Au
th
or
 M
an
us
cr
ip
t
 This article is protected by copyright. All rights reserved 
Table 2.  
Distribution of clinically detectable recurrences  
*Isolated first recurrence site 
(104 patients with isolated first failure) 
All clinically detectable recurrence sites 
(238 total involved sites in 128 patients)  
  n % n % 
Local failure 5 4.8% 13 5.5% 
Pelvic lymph nodes 12 11.5% 35 14.7% 
Retroperitoneal/Abdominal Lymph nodes 13 12.5% 41 17.2% 
Thoracic lymph nodes 3 2.9% 15 6.3% 
Bone 66 63.5% 102 42.9% 
Visceral 5 4.8% 32 13.4% 
*Isolated first recurrence site defined as metastatic disease confined to a single location listed above for at least 3 months before involvement 
of a second site 
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Table 3.  8-year cumulative incidence of all anatomic sites of failure 
  RP+SRT 
(Overall) 
RP+SRT  
(NCCN High-risk) 
Local Failure 2.2% 2.5% 
Pelvic Lymph nodes 6.0% 6.2% 
Retroperitoneal/Abdominal Lymph nodes 4.2% 5.7% 
Thoracic lymph nodes 1.9% 2.6% 
Bone 12.3% 17.7% 
Visceral 2.6% 3.1% 
    
Overall 8-year incidence of local regional 
failure 
8.2% 8.7% 
Overall 8-year incidence of distant failure 21.0% 29.1% 
Abbreviations: NCCN, National Comprehensive Cancer Network; RP=radical prostatectomy; 
SRT=Salvage radiation therapy,  
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Table 4. Stepwise multivariable models 
Model for distant metastases from time of salvage radiotherapy 
Retained Variables† HR 95% CI p-value 
Grade Group 5 2.2 1.4-3.5 <0.001 
Seminal vesicle involvement 2.4 1.5-3.6 <0.001 
Pre-salvage radiotherapy PSA (continuous) 1.2 1.1-1.3 <0.001 
Positive surgical margins 0.4 0.3-0.6 <0.001 
Model for prostate cancer specific mortality from the time of biochemical recurrence 
Retained Variables‡ HR 95% CI p-value 
Grade Group 5 2.4 1.2-4.7 0.01 
Multifocal metastases 2.1 1.1-4.0 0.02 
 
†Variables entered but not retained: pT-stage, ADT use during SRT, Pelvic nodal RT 
‡Variables entered but not retained: Lymphotrophic, Osteotrophic, Gleason Group 1-4, pre-
SRT PSA, Positive surgical margins, pT-stage, ADT use during SRT, Age 
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